Hims acquires Eucalyptus

Hims & Hers, a leader in the telehealth industry, has announced a definitive agreement to acquire Australian digital health company Eucalyptus for up to USD 1.15 billion. This acquisition aims to bolster Hims & Hers' global expansion by integrating Eucalyptus's digital health platforms. The deal includes an initial cash payment of approximately USD 240 million upon closing, with the balance structured as deferred payments over the next 18 months and additional earnouts contingent upon financial performance targets through early 2029.

Eucalyptus, which has an annual revenue run-rate exceeding USD 450 million, will see its CEO Tim Doyle transition to the role of Senior Vice President of International at Hims & Hers. Doyle is tasked with leading Hims & Hers' international operations, leveraging Eucalyptus's market entry expertise and customer-centric approach. This strategic acquisition reflects Hims & Hers’ ambition to enhance its service offerings globally, facilitating access to diverse healthcare services from digital pharmacy solutions to bespoke concierge healthcare models.

For Hims & Hers, acquiring Eucalyptus represents a tactical move to diversify and strengthen its international platform. Eucalyptus, noted for its successful transition to focusing on weight loss brands such as Juniper and Pilot, will integrate its strengths in personalized healthcare and regulatory proficiency into Hims & Hers' broader strategy. CEO Andrew Dudum highlighted that the acquisition is part of the company’s efforts to scale and innovate, leveraging Eucalyptus's existing market presence and operational success.

The telehealth sector continues to experience rapid evolution, with companies like Hims & Hers striving to capture larger shares of global markets. Eucalyptus brings to the table a strong portfolio, having pivoted towards GLP-1 related healthcare services amid changing market demands. This acquisition could position Hims & Hers at a competitive advantage by bolstering its product line and market capabilities at a time when telehealth adoption is increasingly vital.

Looking ahead, the transaction remains subject to customary closing conditions, including regulatory approvals. The successful integration of Eucalyptus’s assets and team into Hims & Hers will be crucial in realising the anticipated synergies of the acquisition. As the deal progresses, stakeholders will closely monitor the execution of deferred payments and the achievement of outlined financial milestones as indicators of the acquisition's longer-term success.